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       A total of 04 Escherichia coli (E.coli) isolates were recovered from women 
urinary tract infections (UTIs) in Al-Hilla teaching hospital, and private clinics. 
Isolates were identified to species level with a VITEK-2 system. Among the 40 
women of UTI, 27(67.5%) had been preceded by a prior UTI and 13(32.5%) had not. 
The susceptibility to 4 antibiotics were tested using disc diffusion test, resulting in 
9(33.3%), 7(26%), 3(11.1%), 1(4%) were resistant to ampicillin, trimethoprim-
sulfamethoxazole, ciprofloxacin, and nitrofurantion, respectively with prior UTI. For 
detection extended spectrum β-lactamase (ESBL) producing E.coli, all 40 isolates 
were tested by using double-disk test method, and then confirmed by using 
combination disk test. The results showed that 10 (25%) were β-lactamase producing 
isolates.   
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Introduction: 
       The pathogens causing urinary tract infections (UTIs) are almost always 
predictable, with E.coli the primary etiologic agent among both outpatients and 
inpatients [1]. The vast majority of UTIs arise in female outpatients, many of whom 
are treated empirically by physicians if their symptoms suggest acute uncomplicated 
bacterial cystitis [2]. Uropathogenic E.coli (UPEC) strain of E.coli is the most 
common pathogen isolated from the patients with UTI, often from the patient’s own 
intestinal flora. Strain-specific virulence factors and host susceptibility give them the 
ability to colonize the urinary tract epithelia selectively, ascending through the 
urethra, bladder, possibly kidney tissue and cavities, triggering inflammatory 
reactions [3]. Guidelines recently published by the Infectious Diseases Society of 
America (IDSA) recommend trimethoprimsulfamethoxazole (SXT) as initial therapy 
for women with acute uncomplicated bacterial cystitis, but only in communities where 
the prevalence of SXT resistance is less than 10 to 20% [4]. The emergence of 
extended-spectrum β-lactamase (ESBL) producing bacteria, particularly E.coli and 
Klebsiella pneumoniae (K. pneumoniae), is now a critical concern for the 
development of therapies against bacterial infection. Since the early 1980s, the 
number of nosocomial infections by ESBL-producing, gram-negative bacteria has 
been increasing worldwide, and β-lactamase production has become a major causative 
agent for increasing resistance to antibiotics [5]. The ESBL genes are mostly plasmid 
encoded, and most ESBLs can be divided into 3 genotypes: TEM, SHV, and CTX-M 
[6]. The major ESBL producer was K. pneumoniae before 2000, and the predominant 
ESBL genotypes were TEM and SHV [7]. E. coli has now become an important 
ESBL carrier. In addition, a genotype CTX-M has become more prevalent worldwide 
compared to the TEM and SHV genotypes [8]. During the 1990s, ESBL-producing 
organisms were described mainly as members of the TEM- and SHV-β-lactamase 
families in E. coli and K. pneumoniae causing nosocomial outbreaks [9]. The 
emergence of E. coli isolates with multiple-antibiotic-resistant phenotypes, involving 
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co-resistance to four or more unrelated families of antibiotics, has been previously 
reported and is considered a serious health concern [10]. Transference of resistance 
determinants by mobile genetic elements including plasmids, transposons, and gene 
cassettes in integrons [11] and the alteration in mar locus regulation are important 
factors that can contribute to the increase in multiresistant bacteria. 
 
The aim of study: 
      Extended spectrum β-lactamases (ESBLs) have emerged as a major threat 
worldwide with limited treatment options; hence the present study was aimed to 
determine the occurrence of ESBLs in E.coli isolates from women patients with UTI. 
   
Materials and methods: 
Bacterial isolates: 
         Fourty E.coli isolates were obtained from urine samples in Al-Hilla/Iraq during 
the period from May  to  July 2014. Urine samples were collected from women 
patients Al-Hilla Marjan teaching hospital, and private clinics in Al-Hilla city. 
Clinical isolates were identified as E.coli based on their morphology, Gram-staining. 
Vitek 2 system was performed to identify species level of E.coli isolates. 
 
Antimicrobial Susceptibility Test: 
1- Disc diffusion test (DD test):  
    The antimicrobial susceptibility patterns of isolates to different antimicrobial agents 
was determined and interpreted according to [11]. Disk diffusion test was used against 
4 antibiotics, the following antimicrobial agents were obtained (from Oxoid, U.K) as 
standard reference disks as known potency for laboratory use: Ampicillin (l0mg), 
trimethoprim-sulfamethoxazol (1.25/ 23.75mg), ciprofloxacin (5mg), and 
nitrofurantion (300mg). 
 
2- Detection of ESBL: 
2-1- with disk diffusion method:  
      The methods proposed by [12] were followed, using 30mg disks of cefotaxime 
(CTX), ceftazidime (CAZ), ceftriaxone (CRO) or aztreonam (AZT) (BBL, Becton 
Dickinson, USA) at a distance of 15mm from a disk of amoxicillin/clavulanic acid 
(AMC) (20/10mg). Positive result is indicated when the inhibition zones around any 
of the cephalosporin disks are augmented in the direction of the disk containing 
clavulanic acid. 
 
2-2 Combination disk test (CDT): 
        The test was performed with Mueller-Hinton agar plates, and disks containing 30 
μg of cefotaxime or ceftazidime with and without 10 μg of clavulanic acid. The test is 
positive if zone diameters increased by ≥5 mm for either cefotaxime, ceftazidime, 
when tested in combination with clavulanic acid versus its zone when tested alone, as 
indicated by the manufacturer or CLSI [11]. 
 
Results and Discussion: 
        A total of 04 Escherichia coli (E.coli) isolates were recovered from women 
urinary tract infections (UTIs) in Al-Hilla teaching hospital, and private clinics. 
Among the 40 woman of UTI, 27(67.5%) had been preceded by a prior UTI. The 
bacterial adhesion to urinary tract mucosa is a critical virulence factor. Type P 
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fimbriae mediate adhesion through recognition of digalactoside type residues 
(Galα1→Gal1β) of  P-type antigens of blood groups. These receptors are expressed in 
epithelial cells of the urinary tract [13].  
        In the present study, resistance to ampicillin occurred in 9 (33.3%) patients with 
a prior history of UTI, and 6 (46.1%) isolates among patients without a prior history. 
The mechanism of resistance to β-lactam antibiotic is mostly due to either production 
of β-lactamases that hydrolyze β-lactam ring, or lack of penicillin receptors on cell 
wall and / or alteration in their permeability to β-lactam  antibiotics preventing the 
uptaking of them [14]. Hassan et al, 2010 [15] found that all E.coli isolates were 
resistant to ampicillin, carbenicillin and ceftazidime, most isolates of  E.coli were 
resistant to cefotaxime (78%), ceftriaxone (93%), ciprofloxacin (82%), levofloxacin 
(67%) and amoxicillin-clavulanic acid (67%). 
        Results showed that resistance to trimethoprim-sulfamethoxazol (TMP-SMZ) 
took place in 7 (26%) isolates with a prior history of UTI, and 5 (38.4%) isolates 
among patients without a prior history. Trimethoprim is a tetrahydrofolate reductase 
inhibitor that, when added to sulfamethoxazole, provides a second step block in the 
folate biosynthetic pathway. TMP-SMZ proved to be bactericidal [16]. Blocking 
folate metabolism at 2 sites decreased the emergence of resistance, nevertheless, 
resistance to TMP-SMZ has occurred because of amino acid substitutions in both 
enzymes, Plasmids (e.g., pSK41) carry the altered genes, which facilitate the spread 
of TMP-SMZ resistance. Exogenous thymidine will render TMP-SMZ inactive, 
because it bypasses the double biosynthetic blockade. Wright et al, 1999 [17] showed 
that resistance to TMP-SMX was present in 67 (15%) of 448 urinary coliform 
isolates. 
         In this study, resistance to ciproﬂoxacin found in 3 (11.1%) isolates with a prior 
history of UTI, and 1 (8%) isolates among those without a prior history. 
Ciprofloxacin, is bacteriocidal drug, affecting Gram positive and Gram negative 
bacteria. Generally anti Gram negative activity is more closely associated with DNA 
gyrase inhibition, whereas anti Gram positive activity is more closely associated with 
bacterial topoisomerase IV inhibition. DNAgyrase, and bacterial topoisomerase IV, 
are vital for dicating the proper topology of DNA which is important for protein 
biosynthesis, DNA  replication and DNA repair, this interference with DNA 
transcription, replication, and repair will promote its cleavage, leading to rapid 
bacterial cell death. Also resistance to ciprofloxacin is most commonly associated 
with genetic-based alterations in the topoisomerases, resulting in decreased drug 
binding. Moreover, decreased porin presence and also decreases their uptake. Active 
uptake seems not to be a significant factor in their absorption although it is believed to 
contribute to distribution and excretion, and particularly with efflux of these agents 
from bacterial cells before they reach their intercellular targets [18]. Arslan et al, 2005 
[19] showed that resistance to ciprofloxacin was present in 32 (42%) of 77 isolates 
from community-acquired urinary tract infections in Turkey. 
        During this study, resistance to nitrofurantion was 1 (4%) among patients with a 
prior history of UTI, and there was no resistance to nitrofurantoin among patients 
without a prior history. Nitrofurans are a group of compounds characterized by the 
presence of one or more nitro-groups on a nitroaromatic or nitroheterocyclic 
backbone. Examples of compounds belonging to this group include furazolidone, 
nitrofurazone and nitrofurantoin: drugs that all display antimicrobial activity and are 
used clinically to treat different types of infections. Nitrofurantoin is taken orally, 
rapidly absorbed and excreted in the urine to generate high therapeutic concentrations 
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[20]. Nitrofurantoin is prescribed for use against uncomplicated lower urinary tract 
infections (UTIs). Studies of E.coli extracts have shown that strains resistant and 
susceptible to nitrofurans differ in their ability to reduce the compounds, [21] 
suggesting that nitrofurans need to be activated by this reducing activity to show their 
antibiotic effect. Furthermore, it has been shown that there are two types of 
nitroreductase activities in E.coli: one type insensitive to oxygen (type I) and the other 
inhibited by oxygen (type II). Chemical analyses indicate that in type I nitroreduction, 
the nitro-moiety of the parent compound is reduced via a sequence of intermediates, 
including a nitroso and hydroxylamine state, to a biologically inactive end product 
where one of the intermediates is thought to be responsible for toxicity. The specific 
identity of the bio-reactive intermediate is not known, but it binds and disrupts 
bacterial DNA and protein and is believed to be hydroxylamine [22]. 
      Karlowsky et al, 2003 [23] Showed that TMP-SMX, ampicillin, nitrofurantoin, 
and ciprofloxacin, susceptibilities for urinary E.coli resistant isolates from female 
outpatients in 1998–2001 were 17.5%, 38%, 0.8%, and 2.3%, respectively. Because 
of the low levels of resistance for nitrofurantoin and ciprofloxacin in vitro, they 
suggested that nitrofurantoin and ciprofloxacin may be used as adequate alternative 
therapy for female outpatients with uncomplicated urinary tract infections when TMP-
SMX cannot be used. The activity of nitrofurantoin and ciprofloxacin against TMP-
SMX resistant E.coli may be an important consideration for patient treatment. 
       All 40 isolates were tested by using double-disk test method for detection 
extended spectrum β-lactamase (ESBL) producing E.coli. The results showed that 10 
(25%) were β-lactamase producing isolates which showed expansion of indicator 
cephalosporin inhibition zone towards amoxicillin-clavulanic acid disk. And then 
confirmed by using combination disk test that showed the same isolates (10) ≥ 5 mm 
increase in cephalosporin inhibition zone with clavulanic acid. Extended spectrum β- 
lactamases (ESBLs) are the enzymes produced by Gram-negative bacilli that have the 
ability to hydrolyze β-lactam antibiotics containing an oxyimino group (third 
generation cephalosporins and aztreonam) and are inhibited by β-lactamase inhibitors 
such as clavulanic acid, sulbactam, and tazobactam [24]. ESBLs are usually plasmid-
mediated β-lactamases, most commonly found in K.pneumoniae, E.coli and other 
Gram-negative bacilli [25]. The number of (ESBL) producing Enterobacteriaceae 
isolated from clinical material derived from either hospitalized patients or those living 
in the community has increased [26]. Studies indicated that the drug resistance rate of 
ESBLs producing E.coli was higher than that of non ESBLs producing E.coli. It was 
also reported that the rate of multiple drug-resistant strain was higher in ESBLs 
producing E.coli than in non ESBLs producing E.coli, and that multiple drugresistant 
strains occurred frequently in drug-resistant strains [27]. Hence more attention should 
be paid clinically to ESBLs producing E.coli, and antibiotics should be used rationally 
according to the results of antimicrobial susceptibility tests. Multiple drug-resistance 
may be related to the extensive use of spectrum β-lactamases. However, its 
mechanism is still uncertain [28]. Lautenbach et al, 2001  [29] demonstrated that Of 
the 33 patients with ESBL-producing E.coli, and K.pneumoniae urinary infection, 25 
(75.8%) of them had infections due to K.pneumoniae and 8 (24.2%) had infections 
due to E.coli. Villar et al, 2013 [30] found that 14 of 37 E.coli were ESBL producers 
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